Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk

3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD

Educational information

This video was recorded at the Congress of the American College of Cardiology (ACC)) 2019.

Faculty

Anne Carol Goldberg, MD is a Professor of Medicine in the Division of Endocrinology, Metabolism and Lipid Research at Washington University School of Medicine in St. Louis, Missouri,, VS.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Read our summary of the results of the CLEAR Wisdom trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.